Rapamycin shows promise in extending lifespan by addressing age-related issues through mTORC1 inhibition, supporting healthier ageing. However, mTORC2 inhibition poses metabolic risks. Current trials focus on finding safe, effective doses to position rapamycin as a preventive measure against age-related diseases.
October 2023 – Springer Nature Link
Key Takeaways
- mTORC1 inhibition supports healthier ageing: Inhibiting mTORC1 pathways appears to reduce age-related cellular damage, potentially extending lifespan by promoting better cellular repair and metabolic balance, essential for sustaining health over time
- Selective targeting of mTOR pathways is essential: While mTORC1 inhibition may aid in longevity, mTORC2 inhibition risks metabolic complications, underscoring the need for precise therapeutic targeting to avoid adverse side effects in longevity treatments
- Dosing optimisation enhances safety and efficacy: Research prioritises identifying safe, effective dosing regimens for rapamycin to balance its benefits with minimal risks, making it a more viable anti-ageing intervention
The evolving evidence on rapamycin’s potential in delaying age-related diseases positions it as a promising compound in anti-ageing therapies, with ongoing trials refining its use for age-related health benefits.
Read the article at: Blagosklonny, Mikhail V. “Blazing a Trail for the Clinical Use of Rapamycin as a Geroprotector.” Ageing and Disease, vol. 15, no. 10, 2024, doi:10.14336/AD.2024.1020.